TG Therapeutics | TGTX - Operating Profit

Stock Price
30.90
Daily Change
1.24 4.18%
Monthly
0.32%
Yearly
8.31%
Q1 Forecast
28.61

TG Therapeutics reported $50.49M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Alaunos Therapeutics USD -1.19M 432K Sep/2025
Amgen USD 3.96B 464M Dec/2025
Ardelyx USD 4.67M 19.07M Sep/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Curis USD -12.51M 40K Jun/2024
Gilead Sciences USD 2.96B 551M Dec/2025
Infinity Pharmaceuticals USD -10.12M 1.39M Jun/2023
J&J USD 5.59B 1.81B Dec/2025
Karyopharm Therapeutics USD -31.28M 5M Dec/2024
Novartis USD 4.5B 363M Sep/2025
Novavax USD -134.02M 296.12M Sep/2024
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
TG Therapeutics USD 50.49M 21.13M Dec/2025
Verastem USD -18.28M 9.78M Jun/2024
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025